reports
Globus Medical Reports First Quarter 2024 Results
Globus Medical Reports First Quarter 2024 Results AUDUBON, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2024. Worldwide net sales were $606.7 million, an increase of 119.3%, or 119.8% on a constant currency basisGAAP net loss for the quarter was $7.1 millionGAAP diluted earnings per share (“EPS”) was ($0.05) and non-GAAP diluted EPS was $0.72Non-GAAP adjusted EBITDA was $166.6 million, or 27.5% of net sales “Since the NuVasive merger closed in Se...
Globus Medical Schedules First Quarter Earnings Release and Conference...
Globus Medical Schedules First Quarter Earnings Release and Conference Call AUDUBON, Pa., April 16, 2024 (GLOBE NEWSWIRE) -- , Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the first quarter ended March 31, 2024 after the market close on Tuesday, May 7, 2024. A copy of the release will be available on the Globus Medical website at . Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live...
Globus Medical Inc: 1 director
A director at Globus Medical Inc sold 10,590 shares at 51.990USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
Globus Medical Reports Fourth Quarter and Full Year 2023 Results
Globus Medical Reports Fourth Quarter and Full Year 2023 Results AUDUBON, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, 2023. Fourth Quarter 2023: Worldwide net sales were $616.5 million, an increase of 124.6%, or 123.8% on a constant currency basisGAAP net income for the quarter was $15.0 millionGAAP diluted earnings per share (“EPS”) was $0.11 and non-GAAP diluted EPS was $0.60Non-GAAP adjusted EBITDA was $17...
Globus Medical Schedules Fourth Quarter and Full Year 2023 Earnings Re...
Globus Medical Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call AUDUBON, Pa., Feb. 13, 2024 (GLOBE NEWSWIRE) -- , Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full year ended December 31, 2023 after the market close on Tuesday, February 20, 2024. A copy of the release will be available on the Globus Medical website at . Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Parti...
Globus Medical promotes Keith Pfeil to Chief Operating Officer and Chi...
Globus Medical promotes Keith Pfeil to Chief Operating Officer and Chief Financial Officer Pfeil takes on expanded responsibilities while Globus fuels its next phase of growth AUDUBON, Pa., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the promotion of Keith Pfeil as chief operating officer (COO) and chief financial officer (CFO). Having served as the Company’s CFO since August 2019, in this expanded role, Pfeil will help further drive the Company's strategic roadmap through business and operational pla...
Globus Medical Reports Preliminary Record Fourth Quarter and Full Year...
Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results AUDUBON, Pa., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ending December 31, 2023. The company anticipates fourth quarter 2023 sales of approximately $615.5 million, an increase of 124.2 percent over the fourth quarter 2022 on an as-reported basis. Full year 2023 sales are expected to be approximately $1.567 billion, an increase of 53.2 percent ove...
Globus Medical Reports Third Quarter 2023 Results
Globus Medical Reports Third Quarter 2023 Results AUDUBON, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2023. The merger with NuVasive, Inc. was completed on September 1, 2023 and results presented within include NuVasive, Inc. results from that closing date. Worldwide net sales were $383.6 million, an increase of 51.0%.GAAP net income for the quarter was $1.0 millionGAAP diluted earnings per share (“EPS”) was $0.01 and non-GAAP diluted EPS w...
Globus Medical Schedules Third Quarter Earnings Release and Conference...
Globus Medical Schedules Third Quarter Earnings Release and Conference Call AUDUBON, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- , Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the third quarter ended September 30, 2023 after the market close on Tuesday, November 7, 2023. A copy of the release will be available on the Globus Medical website at . Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference c...
Five-Year Study Outcomes of the NuVasive Simplify Cervical Disc were P...
Five-Year Study Outcomes of the NuVasive Simplify Cervical Disc were Presented at the North American Spine Society 38th Annual Meeting AUDUBON, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, presented five-year outcomes from the NuVasive study at the North American Spine Society (NASS) 38th Annual Meeting. The study demonstrates positive, long-term clinical outcomes, a high rate of overall composite success at 60 months, and statistical superiority to anterior cervical discectomy fusion (ACDF) procedural outcomes. “...
Twenty Years of the NuVasive XLIF Procedure Celebrated at the Society ...
Twenty Years of the NuVasive XLIF Procedure Celebrated at the Society for Minimally Invasive Spine Surgery 2023 Annual Forum AUDUBON, Pa., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, celebrated twenty years of the NuVasive XLIF procedure at the Society for Minimally Invasive Spine Surgery (SMISS) ’23 Annual Forum. “Very few medical technology innovations have transformed an industry like the NuVasive XLIF procedure. Twenty years of XLIF has produced two decades of unmatched clinical validation, represented by an incred...
Globus Medical and NuVasive to Sponsor and Participate at EUROSPINE 20...
Globus Medical and NuVasive to Sponsor and Participate at EUROSPINE 2023 AUDUBON, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced it will continue its partnership with EUROSPINE as a silver sponsor and will attend EUROSPINE 2023 held October 4 to 6 in Frankfurt. “As leaders in the musculoskeletal device industry, we are committed to procedurally integrated innovation that enables surgeons to deliver more intelligent surgery,” said Dan Scavilla, chief executive officer at Globus Medical. “Our support...
NuVasive Specialized Orthopedics Launches Precice Bone Transport in In...
NuVasive Specialized Orthopedics Launches Precice Bone Transport in International Markets AUDUBON, Pa., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the commercial launch of NuVasive Specialized Orthopedics’ (NSO) Precice Bone Transport system in targeted regions. The latest addition to the less invasive NSO portfolio is now CE-marked and approved and available in select markets. “The NSO difference is our deep commitment to making complex reconstruction simple and more reproducible,” said Pete Ligott...
Globus Medical Completes Merger with NuVasive
Globus Medical Completes Merger with NuVasive —Creates leading global musculoskeletal company——Robust portfolio well-positioned for long-term growth and continued innovation— AUDUBON, Pa., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced it has completed its previously announced merger with NuVasive, Inc. The combined company will provide surgeons and patients with one of the most comprehensive offerings of musculoskeletal procedural solutions and enabling technologies to impact the care continuum. “We...
Globus Medical Reports Second Quarter 2023 Results
Globus Medical Reports Second Quarter 2023 Results AUDUBON, Pa., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2023. Worldwide net sales were $291.6 million, an increase of 10.6%GAAP net income for the quarter was $57.7 millionGAAP diluted earnings per share (“EPS”) was $0.57 and non-GAAP diluted EPS was $0.63Non-GAAP adjusted EBITDA was $96.1 million, or 33.0% of net sales “Globus achieved a record quarter, delivering our highest quarterly rev...
Globus Medical Announces Launch of the MARVEL™ Growing Rod System, the...
Globus Medical Announces Launch of the MARVEL™ Growing Rod System, the company’s first product designed specifically for early onset scoliosis MARVEL™ is Globus Medical’s second major release this year in the pediatric scoliosis space AUDUBON, Pa., July 31, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the commercial launch of the MARVEL™ Growing Rod System, which is designed for pediatric patients with early onset scoliosis to obtain and maintain correction while allowing for growth through minimally invasive di...
Globus Medical Schedules Second Quarter Earnings Release and Conferenc...
Globus Medical Schedules Second Quarter Earnings Release and Conference Call AUDUBON, Pa., July 13, 2023 (GLOBE NEWSWIRE) -- , Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the second quarter ended June 30, 2023 after the market close on Thursday, August 3, 2023. A copy of the release will be available on the Globus Medical website at . Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call ...
Globus Medical Announces FDA Approval for its Non-Fusion Scoliosis Cor...
Globus Medical Announces FDA Approval for its Non-Fusion Scoliosis Correction System, the Latest Advancement for Young Patients with Idiopathic Scoliosis REFLECT™ is approved through the FDA’s Humanitarian Device Exemption pathway AUDUBON, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the REFLECT™ Scoliosis Correction System has been granted approval from the US Food and Drug Administration, as the company’s first humanitarian device. REFLECT™ is designed to correct progressive scoliosis in young pat...
Globus Medical Reports First Quarter 2023 Results
Globus Medical Reports First Quarter 2023 Results AUDUBON, Pa., May 04, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2023. Worldwide net sales were $276.7 million, an increase of 20.0%, or 21.0% on a constant currency basisGAAP net income for the quarter was $49.1 millionGAAP diluted earnings per share (“EPS”) was $0.48 and non-GAAP diluted EPS was $0.53Non-GAAP adjusted EBITDA was $85.1 million, or 30.8% of net sales “Globus achieved a record quarter, delive...
Globus Medical Shareholders Approve Share Issuance for Merger with NuV...
Globus Medical Shareholders Approve Share Issuance for Merger with NuVasive AUDUBON, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- , Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced that at the special meeting of shareholders held earlier today its shareholders voted to approve the issuance of shares of Globus Medical Class A common stock in connection with the proposed merger with NuVasive (NASDAQ: NUVA). As previously announced, under the terms of the merger agreement, Globus Medical will issue 0.75 of a share of Globus Medical Class A common stock in exchange fo...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.